Breaking Delhi Aims for Electric Vehicle Transition by 2027 to Combat Pollution Supreme Court Won’t Reconsider Birthright Citizenship Ruling After Deadline Passes Senate Advances Sanctions Bill Against Russia Following Zelenskyy’s Appeal US Missile Interceptor Stockpiles Significantly Depleted Amidst Iran Conflict, Analysis Shows Denzel Ward Signs Extension, Becomes Highest-Paid Defensive Back in NFL

Tuesday July 28, 2026

Reporter

NanoViricides

4Articles Published

5Communities Covered

Published Articles

Press Release

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

Jul 23

Press Release

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

Jul 13

Press Release

Research Analyst Report on NanoViricides Rates Company “Outperform”; Separately, A “Fireside Chat” Interview of the Company’s President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

Jul 8

Press Release

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

Jul 6